Patents by Inventor Youfa XU

Youfa XU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Safe and stable nimodipine formulation for injection and method for preparing same
    Patent number: 12661344
    Abstract: The present invention relates to the technical field of pharmaceutics, and in particular, to a safe and stable nimodipine formulation for injection and a method for preparing same. The present invention provides a lyophilized nimodipine-cyclodextrin powder for injection, comprising sulfobutylether-?-cyclodextrin, which can significantly improve the solubility, safety, and dilution stability of nimodipine, and increase patient compliance and the convenience of clinical use. Compared with a commercially available nimodipine injection NIMOTOP, the present invention has significant advantages in safety and dilution stability.
    Type: Grant
    Filed: April 4, 2023
    Date of Patent: June 23, 2026
    Assignees: SHANGHAI WEI ER BIOPHARMACEUTICAL TECHNOLOGY CO., LTD., SHANGHAI BAOLONG PHARMACEUTICAL CO., LTD., BAOLONG PHARMACEUTICAL CO., LTD., SHANGHAI BAOLONG ANQING PHARMACEUTICAL CO., LTD.
    Inventors: Xin Wu, Youfa Xu, Zhizhe Lin, Yongjie Huang, Jianming Chen, Yuansheng Zhang, Zhiqin Fu, Xinmei Chen, Hang Chen
  • SAFE AND STABLE NIMODIPINE FORMULATION FOR INJECTION AND METHOD FOR PREPARING SAME
    Publication number: 20250255854
    Abstract: The present invention relates to the technical field of pharmaceutics, and in particular, to a safe and stable nimodipine formulation for injection and a method for preparing same. The present invention provides a lyophilized nimodipine-cyclodextrin powder for injection, comprising sulfobutylether-?-cyclodextrin, which can significantly improve the solubility, safety, and dilution stability of nimodipine, and increase patient compliance and the convenience of clinical use. Compared with a commercially available nimodipine injection NIMOTOP, the present invention has significant advantages in safety and dilution stability.
    Type: Application
    Filed: April 4, 2023
    Publication date: August 14, 2025
    Inventors: Xin Wu, Youfa Xu, Zhizhe Lin, Yongjie Huang, Jianming Chen, Yuansheng Zhang, Zhiqin Fu, Xinmei Chen, Hang Chen
  • Docetaxel palmitate liposome and preparation method thereof
    Publication number: 20210212947
    Abstract: The present invention relates to the technical field of medicine, which provides a liposomal docetaxel palmitate formulation and a method for preparing the said formulation. The liposomal docetaxel palmitate formulation contains docetaxel palmitate as the main drug, a chelating agent, lecithin and DSPE-PEG2000. It is characterized in that docetaxel is prepared into a docetaxel palmitate lipophilic prodrug, thus overcoming the defect that docetaxel cannot be processed into liposomes due to poor hydrophilicity and hydrophobicity. The liposome prescription of this invention contains a chelating agent with a substantive effect that can prolong the action time of the drug in the body, improve the anti-tumor effect and be prepared smoothly. Therefore, the chelating agent in the formulation is the core technical feature of the present invention.
    Type: Application
    Filed: April 26, 2019
    Publication date: July 15, 2021
    Inventors: Jianming CHEN, Baoan GAO, Youfa XU, Xin WU, Yamin SHI, Lang YAN, Zhiqin FU, Xiaoping LI